US74345W1080 - Common Stock
PROPHASE LABS INC
NASDAQ:PRPH (11/12/2024, 8:26:08 PM)
After market: 0.7116 -0.03 (-3.52%)0.7376
0 (-0.19%)
ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. The company is headquartered in New York City, New York and currently employs 113 full-time employees. The firm provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
PROPHASE LABS INC
711 Stewart Ave, Suite 200, Garden City
New York City NEW YORK 11530
P: 12153450919
CEO: Ted Karkus
Employees: 113
Website: https://www.prophaselabs.com/
GARDEN CITY, NY, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics...
GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics...
Introduces DNA Expand Subscription Platform to Enrich Existing DNA Ancestry Data with Comprehensive Health Insights GARDEN CITY, NY, Nov. 04, 2024 ...
Projections for Pharmaloz Manufacturing: Approximately $16-17 Million in Revenue, $6-7 Million in Pre-Tax Earnings for 2025 Strategic Partnership...
GARDEN CITY, NY, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics,...
PRPH stock results show that ProPhase Labs missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Here you can normally see the latest stock twits on PRPH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: